These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22203585)

  • 21. Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.
    Lin G; Pankuch G; Appelbaum PC; Kosowska-Shick K
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6251-4. PubMed ID: 25022588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections.
    Isnard C; Dhalluin A; Malandain D; Bruey Q; Auzou M; Michon J; Giard JC; Guérin F; Cattoir V
    J Glob Antimicrob Resist; 2018 Jun; 13():221-225. PubMed ID: 29421316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
    Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN
    Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.
    Castanheira M; Sader HS; Farrell DJ; Mendes RE; Jones RN
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4779-85. PubMed ID: 22733066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene.
    Arhin FF; Sarmiento I; Moeck G
    Int J Antimicrob Agents; 2014 Jul; 44(1):65-8. PubMed ID: 24906505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.
    Hagihara M; Wiskirchen DE; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2012 Jan; 56(1):202-7. PubMed ID: 22006007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin.
    Vidaillac C; Parra-Ruiz J; Rybak MJ
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):470-3. PubMed ID: 22018937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multivalent approach to drug discovery for novel antibiotics.
    Long DD; Aggen JB; Christensen BG; Judice JK; Hegde SS; Kaniga K; Krause KM; Linsell MS; Moran EJ; Pace JL
    J Antibiot (Tokyo); 2008 Oct; 61(10):595-602. PubMed ID: 19168973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.
    Sader HS; Flamm RK; Farrell DJ; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S181-6. PubMed ID: 22903950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycopeptide and daptomycin susceptibility and vancomycin heteroresistance of methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates from a Greek university hospital.
    Panagea T; Galani I; Souli M; Karantani I; Giamarellou H; Petrikkos G
    Int J Antimicrob Agents; 2011 Nov; 38(5):451-2. PubMed ID: 21840688
    [No Abstract]   [Full Text] [Related]  

  • 31. Prevalence of isolates with reduced glycopeptide susceptibility in orthopedic device-related infections due to methicillin-resistant Staphylococcus aureus.
    Vaudaux P; Ferry T; Uçkay I; François P; Schrenzel J; Harbarth S; Renzoni A
    Eur J Clin Microbiol Infect Dis; 2012 Dec; 31(12):3367-74. PubMed ID: 22833247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA).
    Arhin FF; Sarmiento I; Moeck G
    Int J Antimicrob Agents; 2013 Apr; 41(4):397-8. PubMed ID: 23374976
    [No Abstract]   [Full Text] [Related]  

  • 33. Reduced susceptibility to vancomycin in methicillin resistant staphylococcus aureus: a time for action.
    Amatya R; Devkota P; Gautam A
    Nepal Med Coll J; 2014 Sep; 16(1):42-4. PubMed ID: 25799810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.
    Belley A; Arhin FF; Sarmiento I; Deng H; Rose W; Moeck G
    Antimicrob Agents Chemother; 2013 Jan; 57(1):205-11. PubMed ID: 23089749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin.
    Marconescu P; Graviss EA; Musher DM
    Scand J Infect Dis; 2012 Aug; 44(8):620-2. PubMed ID: 22668202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cleistochlamys kirkii chemical constituents: Antibacterial activity and synergistic effects against resistant Staphylococcus aureus strains.
    Pereira F; Madureira AM; Sancha S; Mulhovo S; Luo X; Duarte A; Ferreira MJ
    J Ethnopharmacol; 2016 Feb; 178():180-7. PubMed ID: 26674158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
    Kebriaei R; Rice SA; Stamper KC; Rybak MJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
    Fernandez J; Abbanat D; Shang W; He W; Amsler K; Hastings J; Queenan AM; Melton JL; Barron AM; Flamm RK; Lynch AS
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1476-84. PubMed ID: 22232278
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Gaikwad V; Gohel T; Panickar S; Chincholkar V; Mangalkar S
    Indian J Pathol Microbiol; 2016; 59(4):496-498. PubMed ID: 27721280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
    Farrell DJ; Flamm RK; Sader HS; Jones RN
    Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.